secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001140361-25-000837
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports ~$820M cash; three Phase 3 melanoma trials; new autoimmune candidate
--------------------------------------------------------------------------------

- Preliminary cash ~$820M as of Dec 31, 2024; Pharmakon loan prepaid in full.
- Three Phase 3 trials enrolling in melanoma (TEBE-AM, PRISM-MEL-301, ATOM); first topline data expected 2026.
- New autoimmune candidate IMC-U120AI (CD1a x PD1) for atopic dermatitis; CTA planned 2026.
- Initial HIV Phase 1 multiple ascending dose data for IMC-M113V expected Q1 2025.
- Travis Coy appointed EVP, CFO and Head of Corporate Development (ex-Eli Lilly).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/0001140361-25-000837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer